Class 2 Medicines Recall: Zaditen 0.25 mg/ml, eye drops, solution (Laboratoires Théa)
MHRA Class 2 Medicines Recall: Zaditen 0.25 mg/ml, eye drops, solution (Laboratoires Théa)
Drug alert number: EL(25)A/34
Date issued: 07 July 2025
Laboratoires Théa trading as Thea Pharmaceuticals Limited have notified the MHRA of an out of specification event related to environmental monitoring during manufacturing, which may increase the risk of microbial contamination of the medicinal product.
DMRC reference number:DMRC-35933479
Company name: Laboratoires Théa
Medicine Details
Product name: Zaditen 0.25 mg/ml, eye drops, solution PL: 20162/0019
Active ingredient: ketotifen fumarate
SNOMED code: 388511000001106
GTIN: 3662042000874
Affected Lot Batch Numbers:
| Batch No. | Expiry Date | Pack Size | First Distributed |
| 4V64 | 30/09/2026 | 5mL | 27/01/2025 |
Background
Laboratoires Théa trading as Thea Pharmaceuticals Limited have notified the MHRA of an out of specification event related to environmental monitoring during manufacturing, which may increase the risk of microbial contamination of the medicinal product. As a precautionary measure the specific batch mentioned in this notification is being recalled. To date, Thea Pharmaceuticals Limited have not received any reports of adverse incidents or product quality complaints related to this potential defect.
Advice for Healthcare Professionals
Stop supplying the above batch immediately. Quarantine all stock and return it to your supplier using your supplier’s approved process.
Thea Pharmaceuticals can confirm 11,360 packs of this batch were released and distributed, no reported adverse events or product quality complaints received to date.
View the full alert here.
Advice for Patients
No further action is required by patients as this is a Pharmacy and Wholesaler level recall related to a specific batch of Zaditen 0.25 mg/ml, eye drops, solution.
Whilst the recall is precautionary and no adverse events have been reported by Thea Pharmaceuticals Limited, if any side effects were to be observed, these would be related to ocular infection and may include conjunctivitis, keratitis, and/or blepharitis, or, for susceptible patients, could be a more severe infection. Patients who experience adverse reactions or have any questions about the medication should seek medical attention. Any suspected adverse reactions should also be reported via the MHRA Yellow Card scheme.
Additional information
For stock control enquiries please contact:
- For pharmacies supplied by a wholesaler, returns should be made via the wholesaler.
- For wholesalers, please contact Mawdsleys PreWholesaler (MPW) customer services using e-mail address customer.services@mpwpharma.co.uk
- For healthcare establishments: please arrange local destruction and make a claim through Mawdsleys PreWholesaler customer.services@mpwpharma.co.uk
For more information or medical information please call 0345 521 1290 (and select option 3) or e-mail thea-pharma@medinformation.co.uk
For stock control enquiries please email customer.services@mpwpharma.co.uk
